United Therapeutics Corp (NASDAQ:UTHR) does about 508.96K shares in volume on a normal day but saw 2801321 shares change hands in the recent trading day. The company now has a market cap of 12.69B USD. Its current market price is $281.36, marking a decrease of -14.32% compared to the previous close of $328.40. The 52 week high reached by this stock is $417.82 whilst the lowest price level in 52 weeks is $266.98. The script in recent trading has seen the stock touch a high of $314 and a low of $314.
7 analysts observing the United Therapeutics Corp (UTHR) stock have set the 12-month price targets for the company’s shares at between $314 and $314. The consensus objective for the share price is $402.09, suggesting that the stock has a potential upside of 30.03% over the period. The median price target is 10.39% away from the current levels at $314.
FactSet Research has provided data showing that 7 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 5 analysts have rated it as a buy and 2 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 02, 2025 when Cantor Fitzgerald initiated the stock to “Overweight” and issued a price target of $405. BofA Securities upgraded its price target at $314.
The current price level is -10.06%, -6.93%, and -17.70% away from its SMA20, SMA50, and SMA200 respectively, with the UTHR price moving above the 50-day SMA on current market day. United Therapeutics Corp (UTHR) stock is down -13.21% over the week and -6.66% over the past month. Its price is -20.26% year-to-date and 1.79% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 7.06 and 27.68 for whole year. Expected sales for next quarter are $831.58M, which analysts say will come at $3.22B for the current fiscal year and next year at $3.42B. In addition, estimates put the company’s current quarterly revenue at an average of $802.13M.
Its 12-month price target is $314. To reach the target analysts have set, the stock logically needs to grow 30.03 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $314, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $314.
Outstanding shares total 45.07M with insiders holding 1.82% of the shares and institutional holders owning 101.40% of the company’s common stock. The company has a return on investment of 17.79% and return on equity of 19.94%. The price to earnings ratio (P/E ratio) amounts to 11.23 while the forward price to earnings ratio is 9.57. The beta has a value of 0.56. Price to book ratio is 1.86 and price to sales ratio is 4.24.
